Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621

Kymera Therapeutics (KYMR) announced positive clinical results from the BroADen Phase 1b atopic dermatitis clinical trial of KT-621, its first-in-class, oral STAT6 degrader medicine. Key points: KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis patients; KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC, Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions; Robust clinical activity was observed across all disease endpoints measured including mean 63% EASI reduction and mean 40% peak pruritus NRS reduction for all patients; Patients with comorbid asthma showed a median 56% reduction in FeNO and meaningful improvements in asthma control, and those with comorbid allergic rhinitis experienced significant symptom and quality-of-life benefits; KT-621 was well-tolerated with no serious adverse events, no treatment related adverse events, no reported cases of conjunctivitis and no clinically relevant changes in vital signs, lab tests or ECGs; KT-621 BROADEN2 Phase 2b trial in moderate to severe AD is ongoing, with data expected by mid-2027; Phase 2b BREADTH trial in moderate to severe asthma patients is on track to start 1Q26